MEDIPOST announced treatment of the first U.S. participant in a Phase III clinical trial evaluating its investigational mesenchymal stem cell (MSC) therapy to treat symptomatic cartilage defects in adults with knee osteoarthritis.
FDA has agreed that this single pivotal study, supported by confirmatory evidence from prior Phase III trials in South Korea and Japan together with Korean real-world evidence, can serve as the basis for MEDIPOST’s planned U.S. Biologics License Application.
MEDIPOST announced treatment of the first U.S. participant in a Phase III clinical trial evaluating its investigational mesenchymal stem cell (MSC) therapy to treat symptomatic cartilage defects in adults with knee osteoarthritis.
FDA has agreed that this single pivotal study, supported by confirmatory evidence from prior Phase III trials...
MEDIPOST announced treatment of the first U.S. participant in a Phase III clinical trial evaluating its investigational mesenchymal stem cell (MSC) therapy to treat symptomatic cartilage defects in adults with knee osteoarthritis.
FDA has agreed that this single pivotal study, supported by confirmatory evidence from prior Phase III trials in South Korea and Japan together with Korean real-world evidence, can serve as the basis for MEDIPOST’s planned U.S. Biologics License Application.
Copy to clipboard 
